Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB575 in Asthma
NCT07732023Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing SKB575 with Placebo (2 arms). Primary endpoints: Adverse Events at 32 weeks and Fractional Exhaled Nitric Oxide at 8 weeks. Started Aug 2026; status: recruiting.
02
Drugs
HBM7575
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07732023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732023.